Method for detecting cancer using CAPRIN-1 as a marker

Patent metadata

Field	Value
Publication number	US-11137401-B2
Application number	US-200913057515-A
Country	US
Kind code	B2
Filing date	Aug 5, 2009
Priority date	Aug 5, 2008
Publication date	Oct 5, 2021
Grant date	Oct 5, 2021

Abstract

The present invention relates to a method for detecting cancer, comprising measuring the expression of a polypeptide having a reactivity of binding to an antibody against a CAPRIN-1 protein having an amino acid sequence shown in any one of the even-numbered SEQ ID NOS: 2-30 in the Sequence Listing via an antigen-antibody reaction in a sample separated from a living organism, and, a reagent for detecting a cancer comprising the CAPRIN-1 protein or a fragment thereof, an antibody against the CAPRIN-1 protein or a fragment thereof, or a polynucleotide encoding the CAPRIN-1 protein or a fragment thereof.

First claim

The invention claimed is:

1. A method for detecting a cancer, comprising:
obtaining an antibody or antigen binding fragment thereof which binds a CAPRIN-1 protein having any one of the amino acid sequences shown in the even-numbered SEQ ID NOS: 2-30 in the Sequence Listing by selecting by screening antibodies isolated against CAPRIN-1 protein for binding to CAPRIN-1 protein on a surface of a cancer cell,
detecting a CAPRIN-1 protein expression on a surface of a cell in a sample from a human by utilizing the antibody or antigen binding fragment thereof,
identifying the human as having cancer by detecting the CAPRIN-1 expression on the surface of the cell in the sample separated from the human, and
treating the human for the cancer,
wherein the treatment comprises an anticancer agent, hormone therapy, radiotherapy and/or surgery.

2. The method according to claim 1 , wherein the CAPRIN-1 protein to be measured is a CAPRIN-1 protein having any one of the amino acid sequences shown in the even-numbered SEQ ID NOS: 2-30 or a polypeptide having 85% or more sequence identity with the CAPRIN-1 protein.

3. The method according to claim 1 , wherein the sample is serum or blood plasma.

4. The method according to claim 1 further comprising detecting the malignancy of a cancer based on the fact that the malignancy of cancer is high when the expression level of the CAPRIN-1 protein is higher than that of a control.

5. The method according to claim 1 further comprising detecting the progression of cancer on the basis of the indicator that the extent of cancer is advanced when the expression level of the CAPRIN-1 protein is higher than that of a control.

6. The method according to claim 1 , wherein the cancer is at least one type of cancer selected from the group consisting of brain tumor, squamous cell carcinoma of the head, neck, lung, uterus or esophagus, melanoma, adenocarcinoma of the lung or uterus, renal cancer, malignant mixed tumor, hepatocellular carcinoma, basal cell carcinoma, acanthoma-like gingival tumor, tumor of the oral cavity, perianal adenocarcinoma, anal sac tumor, anal sac apocrine adenocarcinoma, sertoli cell carcinoma, cancer of vaginal vestibule, sebaceous adenocarcinoma, sebaceous epithelioma, sebaceous adenoma, sweat gland carcinoma, intranasal adenocarcinoma, nasal adenocarcinoma, thyroid cancer, large-bowel cancer, bronchial adenocarcinoma, adenocarcinoma, ductal carcinoma, breast adenocarcinoma, composite type breast adenocarcinoma, malignant mammary mixed tumor, intraductal papillary adenocarcinoma, fibrosarcoma, hemangiopericytoma, osteosarcoma, chondrosarcoma, soft tissue sarcoma, histiocytic sarcoma, myxosarcoma, undifferentiated sarcoma, lung cancer, mastocytoma, cutaneous leiomyoma, intraperitoneal leiomyoma, leiomyoma, chronic lymphocytic leukemia, lymphoma, gastrointestinal lymphoma, digestive lymphoma, small-cell-to-medium-cell lymphoma, adrenomedullary tumor, granulosa cell tumor, and pheochromocytoma.

7. The method according to claim 1 , wherein the antibody or antigen binding fragment thereof specifically binds a fragment of the CAPRIN-1 protein consisting of the amino acid sequence shown in SEQ ID NO: 43 or 61.

8. The method according to claim 1 , wherein the cancer is breast cancer.

9. A method for detecting a cancer, comprising:
obtaining an antibody or antigen binding fragment thereof which binds a CAPRIN-1 protein having any one of the amino acid sequences shown in the even-numbered SEQ ID NOS: 2-30 in the Sequence Listing by selecting by screening antibodies isolated against CAPRIN-1 protein for binding to CAPRIN-1 protein on a surface of a cancer cell,
contacting a cell separated from a human with the antibody or antigen-binding fragment thereof,
detecting a CAPRIN-1 protein expression on the surface of the cell separated from the human,
identifying the human as having cancer by detecting the CAPRIN-1 protein expression on the surface of the cell separated from the human, and
treating the human for the cancer,
wherein the treatment comprises an anticancer agent, hormone therapy, radiotherapy and/or surgery.

10. The method according to claim 9 , wherein the antibody or an antigen-binding fragment thereof which specifically binds a CAPRIN-1 protein expressed on the cell surface of a cancer cell specifically binds a fragment of the CAPRIN-1 protein consisting of the amino acid sequence shown in SEQ ID NO: 43 or 61.

11. The method according to claim 9 , wherein the cancer is breast cancer.

12. The method according to claim 9 , wherein the cancer is at least one type of cancer selected from the group consisting of brain tumor, squamous cell carcinoma of the head, neck, lung, uterus or esophagus, melanoma, adenocarcinoma of the lung or uterus, renal cancer, malignant mixed tumor, hepatocellular carcinoma, basal cell carcinoma, acanthoma-like gingival tumor, tumor of the oral cavity, perianal adenocarcinoma, anal sac tumor, anal sac apocrine adenocarcinoma, sertoli cell carcinoma, cancer of vaginal vestibule, sebaceous adenocarcinoma, sebaceous epithelioma, sebaceous adenoma, sweat gland carcinoma, intranasal adenocarcinoma, nasal adenocarcinoma, thyroid cancer, large-bowel cancer, bronchial adenocarcinoma, adenocarcinoma, ductal carcinoma, breast adenocarcinoma, composite type breast adenocarcinoma, malignant mammary mixed tumor, intraductal papillary adenocarcinoma, fibrosarcoma, hemangiopericytoma, osteosarcoma, chondrosarcoma, soft tissue sarcoma, histiocytic sarcoma, myxosarcoma, undifferentiated sarcoma, lung cancer, mastocytoma, cutaneous leiomyoma, intraperitoneal leiomyoma, leiomyoma, chronic lymphocytic leukemia, lymphoma, gastrointestinal lymphoma, digestive lymphoma, small-cell-to-medium-cell lymphoma, adrenomedullary tumor, granulosa cell tumor, and pheochromocytoma.

13. A method for detecting a cancer, comprising:
obtaining an antibody or antigen binding fragment thereof which binds a CAPRIN-1 protein by selecting by screening antibodies isolated against CAPRIN-1 protein for binding to CAPRIN-1 protein on a surface of a cancer cell,
detecting a CAPRIN-1 protein expression on a surface of a cell in a sample from a human by utilizing the antibody or antigen binding fragment thereof,
identifying the human as having cancer by detecting the CAPRIN-1 protein expression on the surface of the cell separated from the human, and
treating the human for the cancer,
wherein the treatment comprises an anticancer agent, hormone therapy, radiotherapy and/or surgery.

14. The method according to claim 13 , wherein the antibody or antigen binding fragment thereof specifically binds a fragment of the CAPRIN-1 protein consisting of the amino acid sequence shown in SEQ ID NO: 43 or 61.

15. The method according to claim 13 , wherein the cancer is breast cancer.

16. The method according to claim 13 , wherein the cancer is at least one type of cancer selected from the group consisting of brain tumor, squamous cell carcinoma of the head, neck, lung, uterus or esophagus, melanoma, adenocarcinoma of the lung or uterus, renal cancer, malignant mixed tumor, hepatocellular carcinoma, basal cell carcinoma, acanthoma-like gingival tumor, tumor of the oral cavity, perianal adenocarcinoma, anal sac tumor, anal sac apocrine adenocarcinoma, sertoli cell carcinoma, cancer of vaginal vestibule, sebaceous adenocarcinoma, sebaceous epithelioma, sebaceous adenoma, sweat gland carcinoma, intranasal adenocarcinoma, nasal adenocarcinoma, thyroid cancer, large-bowel cancer, bronchial adenocarcinoma, adenocarcinoma, ductal carcinoma, breast adenocarcinoma, composite type breast adenocarcinoma, malign

Assignees

• Okano Fumiyoshi
• Suzuki Kana
• Toray Industries

Inventors

• Okano Fumiyoshi
• Suzuki Kana

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57515 Primary

  of the breast · CPC title

• G01N33/575

  for cancer · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title